Pfizer (NYSE:PFE) Trading 4.5% Higher – Here’s What Happened

Shares of Pfizer Inc. (NYSE:PFE) traded up 4.5% during trading on Tuesday . The stock traded as high as $25.51 and last traded at $25.49. 139,290,663 shares traded hands during trading, an increase of 176% from the average session volume of 50,447,570 shares. The stock had previously closed at $24.39.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.18.

Pfizer Stock Up 4.5%

The firm’s fifty day moving average is $24.74 and its 200-day moving average is $24.39. The company has a market capitalization of $144.93 billion, a P/E ratio of 13.56, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Diversify Wealth Management LLC boosted its stake in Pfizer by 6.6% during the first quarter. Diversify Wealth Management LLC now owns 11,460 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 710 shares in the last quarter. Kathmere Capital Management LLC acquired a new position in shares of Pfizer during the first quarter valued at about $242,000. Finally, Schechter Investment Advisors LLC boosted its position in shares of Pfizer by 108.4% during the 1st quarter. Schechter Investment Advisors LLC now owns 17,456 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 9,079 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.